Search Results 71-80 of 17172 for Amine

  1. A Study of an Implantable System for Remodulin Post Approval - Mayo Clinic

    Inclusion Criteria: Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements ...

  2. Creative Commons creativecommons licenses.

  3. Publications - Elise C. Carey, M.D. - Mayo Clinic

    Palliative Care, version 1.2025 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), nccn.org. 2025. Sanders JJ, Benotti E, Jaramillo C, ...

  4. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

    About this study. The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination ...

  5. Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. - Mayo Clinic

    History of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of ...

  6. News - Nilufer Taner, M.D., Ph.D. - Mayo Clinic

    Nilufer Taner, M.D., Ph.D. Neurologist. Request an Appointment · Overview · News ...

  7. Brain tumor - Doctors and departments - Mayo Clinic

    Learn about our team of brain tumor doctors and surgeons who are researching new ways of diagnosing and treating this condition.

  8. Dominantly Inherited Alzheimer Network (DIAN) - Mayo Clinic

    The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's ...

  9. Oncology (Medical) - Clinical trials

    [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

  10. Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) - Mayo Clinic

    This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab ( ...